Ocrevus Climbing as First-line DMT for RRMS Among Neurologists Surveyed in Spherix Report From: Multiple Sclerosis News Today By: Alice Melao Ocrevus Climbing as First-line DMT for RRMS Among Neurologists Surveyed in Spherix Report Spherix Global Insights2018-09-24T15:38:12+00:00 Related Posts Survey Finds Cimzia Prescriptions for nr-axSpA on the Rise in US May 18, 2020 Ocrevus Use Still Growing in Europe But Challenges on Horizon, Spherix Reports April 15, 2020 COVID-19 is Bad News for New Drug Launches. Which Will Suffer Most? April 3, 2020 AbbVie Prompts Patients to ‘take on’ Arthritis in First Rinvoq DTC Ad March 2, 2020 Ocrevus Use Rises Among New Starters with RRMS, Loses Ground to Other Therapies in PPMS February 14, 2020
